Aflac Inc offers supplemental health insurance and life insurance in the United States and Japan... Show more
Aflac Incorporated operates primarily through two segments: Aflac Japan, the leading provider of cancer and medical insurance policies in force, and Aflac U.S., the top provider of supplemental health insurance products sold at the worksite. This focused approach emphasizes products that address gaps in primary coverage, such as out-of-pocket medical expenses and income protection.
Competitive advantages stem from established distribution networks, including agents, brokers, employers, and affinity channels in Japan. The company’s emphasis on underwriting discipline and a large in-force book supports stable earnings and capital generation. Medium-term positioning centers on maintaining leadership in core supplemental categories while pursuing measured growth in U.S. voluntary benefits and operational efficiencies through technology investments.
Quarterly earnings reports will provide updates on premium sales, persistency, and investment income, directly influencing views on near-term momentum. Management commentary on capital deployment, including dividends and share repurchases, often shapes investor sentiment around shareholder returns.
Analyst rating changes or price-target revisions could follow earnings or macroeconomic developments. Current consensus from approximately 12–15 firms leans toward Hold or Neutral, with limited recent upgrades or downgrades noted in available data. Any material shifts in recommendations would likely reflect evolving outlooks on Japan sales trends or U.S. worksite penetration.
Broader industry or regulatory announcements, such as changes affecting supplemental insurance distribution or healthcare reimbursement, may also act as catalysts by altering the competitive or operating environment.
The supplemental insurance sector remains sensitive to interest rate environments, as investment portfolios generate a significant portion of earnings. Rising rates can support investment income but may pressure new business volumes if they affect consumer affordability.
Demographic trends, including aging populations in Japan, support demand for medical and cancer coverage, while U.S. healthcare cost inflation underscores the value of supplemental protection. Regulatory changes in insurance or healthcare policy could influence product design and distribution, requiring ongoing adaptation. Geopolitical or economic developments affecting consumer confidence may also impact sales cycles in both markets.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. For additional insights on market movements, explore the Trend Prediction Engine.
Looking to 2026 and beyond, Aflac’s trajectory will likely hinge on sustained execution in its core markets. Market expansion opportunities center on deeper U.S. worksite penetration and continued relevance of supplemental products amid evolving healthcare needs. Cost structure evolution through digital transformation and operational efficiencies could support margin sustainability.
Technology transitions, including enhanced digital sales and service capabilities, represent ongoing priorities. Competitive threats may arise from new entrants or shifts in primary insurance coverage. Regulatory developments in both Japan and the U.S. will require monitoring, particularly around product approvals and distribution practices.
Capital allocation priorities emphasize balanced returns to shareholders alongside prudent growth investments. Consensus analyst expectations, reflected in the prevailing Hold stance and price targets below recent trading levels, suggest a cautious but stable long-term market assumption focused on disciplined performance rather than aggressive expansion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a provider of supplemental life and health insurance services
Industry LifeHealthInsurance
A.I.dvisor indicates that over the last year, AFL has been loosely correlated with CNO. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if AFL jumps, then CNO could also see price increases.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AFL advanced for three days, in of 366 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 265 cases where AFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for AFL moved out of overbought territory on July 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AFL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AFL broke above its upper Bollinger Band on July 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. AFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.165) is normal, around the industry mean (1.521). P/E Ratio (14.569) is within average values for comparable stocks, (13.865). AFL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.485). Dividend Yield (0.019) settles around the average of (0.044) among similar stocks. AFL's P/S Ratio (3.668) is slightly higher than the industry average of (1.443).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.